All In MedTech

Device Trial Radar · NCT00386542

Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children

Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-free Jet Injection of Reduced-dose, Intradermal Influenza Vaccine (INF) Administered to >= 6 to < 24 Month-old Infants and Toddlers in the Dominican Republic

Last checked: Nov 20, 2026Latest source record: Aug 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Actual

Start

Oct 2006

Primary completion

Nov 2009

Study completion May 2010

Sponsor

Lead sponsor
Pedro MoroFederal agency
Sponsor type
Federal agency
Collaborators
Fundación Dominicana de Infectología, Santo Domingo, Dominican Republic; Hospital Infantil Dr. Robert Reid Cabral; World Health Organization; Pan American Health Organization; PATH; Bioject Medical Technologies, Inc.; MCM Vaccines B.V.
First posted
Oct 11, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 24 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a sequential phase I and II, controlled, double-blinded study to determine whether immune responses suggesting protection against influenza can safely be induced in young children by two reduced doses one month apart of 0.1 mL of a trivalent inactivated influenza vaccine (INF) administered by the intradermal (ID) route with an investigational ID spacer on a United States (U.S.)-licensed needle-free jet injector (JI), compared to two standard intramuscular (IM) 0.25 mL doses by needle-syringe (N-S) in this age group. The locale is a developing country where financial restraints for the use of full-dose influenza vaccine would limit protection from an influenza pandemic threat, where N-Ss pose dangers and drawbacks in clinical use, and where Mantoux-type N-S ID injections are difficult to administer during mass campaigns.

Conditions

  • Influenza

Interventions

  • Vaxigrip® trivalent inactivated influenza vaccineBiological

    See full description elsewhere in this record.

  • Intradermal spacer on Biojector® 2000 jet injectorDevice

    See elsewhere in this record for full description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rates of seroconversion (SC) on HI assay 1 month after dose 2. SC defined as titer >= 40 among initial-seronegatives (titer < 8 on day 0); OR, a followup titer which rises >= 4-fold.Time frame: One month after each of doses 1 and 2.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Infantíl Dr. Robert Reid Cabral

    Santo Domingo, Nacional, Dominican Republic

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.